“The line between ACR and ARHP sessions has totally blurred,” said Donah Zack Crawford, MA, during the presentation, “Highlights from the 2011 ARHP Sessions,” here at the 2011 ACR/ARHP Annual Scientific Meeting held in Chicago in November 2011.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Maintenance of Certification Is Not Just for the Young
I certainly am relieved to know that I will never need to recertify with the American Board of Internal Medicine Maintenance of Certification, but this feeling is shadowed by a deep sense of shame. I decided to step up and take advantage of all the wonderful recertification programs the ACR has to offer.
Gout – Rheumatology’s Royal Pain
Gout is a common rheumatic disease often characterized by swelling, redness, and intense pain in the big toe. Once thought to be an exclusive disease of the wealthy who overindulged in food and spirits, gout has become a royal pain for millions of Americans.
Patient Fact Sheet – Gout
Gout is a painful and potentially disabling form of arthritis that has been recognized since ancient times. Treatments are available to control most cases of gout, but diagnosing this disorder can be difficult, and treatment plans often have to be tailored for each person.
A Journey Begins with the First Step
The ACR Research and Education Foundation (REF) has launched the Action Alliance network, a program that calls on rheumatologists, investigators, and health professionals to join the REF in asking patients and families to be a part of the conversation. The Action Alliance consists of two programs working together: From the Field Speakers Bureau and Patients and Families for Progress.
Magnify Rheumatology’s Legislative Impact this Month
Members of the ACR’s Executive, Government Affairs, and RheumPAC Committees, along with the Affiliate Society Council, attended 75 meetings with legislators and their staff. These meetings are critical to advancing awareness of rheumatology and the issues affecting your profession and patients.
ACR’s Advocacy Toolkit
Ways to contact your member of Congress; tips for communicating with your member of Congress; ways to get patients involved; and donloadable briefs, posters, and brochures.
ACR Partners with Patient Organizations
The ACR met with representatives from 14 patient advocacy organizations in Washington, D.C., to discuss mutual advocacy and legislative objectives.
Pointers for Rheumatologists Considering AMA Membership
Join the AMA. Don’t join because you agree with everything the AMA does. Join so we, as rheumatologists, will continue to have a voice and make a difference.